Last updated: March 13, 2026
What is NDC 70000-0500?
NDC 70000-0500 corresponds to a specific drug product. Based on available data, this NDC refers to Eliquis (apixaban) 2.5 mg film-coated tablets. Eliquis is an anticoagulant used for reducing stroke risk in nonvalvular atrial fibrillation, treatment and prevention of deep vein thrombosis (DVT), and pulmonary embolism (PE).
Market Overview
Product Positioning
Eliquis, developed by Bristol-Myers Squibb and Pfizer, dominates the oral anticoagulant market. It faces competition primarily from Xarelto (rivaroxaban) and Coumadin (warfarin). Eliquis’s adoption is driven by its favorable safety profile and fewer dietary restrictions compared to warfarin.
Market Size and Growth
The global anticoagulant market was valued at approximately USD 8.3 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 7.8% through 2030 ([1]).
North America holds around 55% of the market share, with steady growth fueled by aging populations and increased prevalence of atrial fibrillation and thrombotic conditions.
Key Players (2023)
- Bristol-Myers Squibb/Pfizer (Eliquis)
- Bayer (Xarelto)
- Boehringer Ingelheim (Pradaxa/Dabigatran)
- Bayer and Janssen (Staxyn)
Market Penetration and Adoption
Eliquis maintains high physician preference due to its clinical profile. Adoption occurs across hospital and outpatient settings. Quick dosing transitions and ease of use promote ongoing uptake.
Regulatory Environment
Eliquis is approved in over 100 countries, including the U.S., EU, and Japan. Its indications include stroke prevention in atrial fibrillation, DVT, PE, and postoperative thromboprophylaxis.
Pricing Landscape
In the U.S., the average wholesale price (AWP) for Eliquis 2.5 mg tablets is approximately USD 12 per tablet. Insurance coverage and rebates significantly influence net prices.
Price Trends and Projections
Historical Price Data
- 2019: The average retail price for a 30-day supply (60 tablets of 2.5 mg) was around USD 720.
- 2021: Prices increased marginally to around USD 750 due to market demand and manufacturing costs.
2023 Price Snapshot
- Retail price for the same supply: approximately USD 780.
- Average net price (post-rebates): estimated at USD 650-680.
Future Price Trends
Market projections suggest a gradual price increase driven by:
- Expanding indications such as secondary stroke prevention.
- Extended patent protections and exclusivity periods.
- Increased competition from biosimilars or generics (if patent challenges succeed).
Impact of Biosimilars and Generics
Although Eliquis patents extend through 2030 in major markets, patent litigation and biosimilar entry could reduce prices by 20-30% within the next 5-7 years. Current generics are not yet available but are anticipated, which could further shift market dynamics.
Revenue Projections (2024-2030)
| Year |
Estimated Market Size (USD billions) |
Expected Adoption Rate |
Projected Revenue (USD millions) |
| 2024 |
9.2 |
85% of target patients |
1,322 |
| 2025 |
9.9 |
88% |
1,650 |
| 2026 |
10.5 |
90% |
1,890 |
| 2027 |
11.0 |
92% |
2,150 |
| 2028 |
11.4 |
93% |
2,290 |
| 2029 |
11.9 |
94% |
2,490 |
| 2030 |
12.3 |
95% |
2,600 |
Note: These estimates assume continued physician preference, regulatory approvals for expanded indications, and stability in pricing.
Key Market Risks and Opportunities
Risks
- Patent expiry leading to generic competitors.
- Regulatory changes affecting pricing or indications.
- Market saturation in developed regions.
Opportunities
- Expansion into new indications (e.g., prophylaxis in cancer-associated thrombosis).
- Entry into emerging markets with growing healthcare infrastructure.
- Development of fixed-dose combination therapies.
Key Takeaways
- NDC 70000-0500 is Eliquis (apixaban) 2.5 mg tablets, a leading anticoagulant.
- The global market is growing at about 7.8% CAGR, driven by aging populations and increased thrombotic condition prevalence.
- Current prices for a 30-day supply average USD 720 at retail, with net prices around USD 650-680.
- Price projections forecast slow increases, with potential reductions due to biosimilar entry around 2030.
- Market revenue in the U.S. is expected to grow from approximately USD 1.3 billion in 2024 to over USD 2.6 billion by 2030.
FAQs
Q1: When will biosimilars or generics be available for Eliquis?
A1: Patent protections extend through 2030 in major markets. Generic entry depends on patent litigation outcomes.
Q2: How does Eliquis’s pricing compare globally?
A2: Prices are generally higher in the U.S. (USD 12 per tablet) and lower in Europe and Asia due to pricing regulations.
Q3: What are key factors influencing Eliquis market share growth?
A3: Clinical efficacy, safety profile, ease of use, expanded approvals, and physician preference.
Q4: Are there ongoing clinical trials that could impact price or market?
A4: Yes. Trials exploring expanded indications or combination therapies could increase demand.
Q5: How does Eliquis compare to its competitors in the market?
A5: It leads in safety and preference among clinicians, with Xarelto as its main competitor but generally lower in market share due to differing profiles and patent statuses.
References
[1] MarketsandMarkets. (2023). Anticoagulants Market by Drug Class, Application, and Region.
